Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry – Vedolizumab

Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD (191 with Crohn's disease (CD) and 119 patients with ulcerative colitis (UC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Biemans, Vince B.C., van der Woude, C. Janneke, Dijkstra, Gerard, van der Meulen‐de Jong, Andrea E., Oldenburg, Bas, de Boer, Nanne K., Löwenberg, Mark, Srivastava, Nidhi, Bodelier, Alexander G.L., West, Rachel L., Jansen, Jeroen M., de Vries, Annemarie C., Haans, Jeoffrey J.L., de Jong, Dirk J., Pierik, Marie J., Hoentjen, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232860/
https://www.ncbi.nlm.nih.gov/pubmed/31677154
http://dx.doi.org/10.1002/cpt.1712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232860/
https://www.ncbi.nlm.nih.gov/pubmed/31677154
http://dx.doi.org/10.1002/cpt.1712

Ejemplares similares